March 11, 2026. 230 items curated for clinical relevance.
Above Threshold
Alabama Medical Cannabis Sales Gear for Spring 2026 Launch
Summary
Alabama’s medical cannabis program is preparing to launch retail sales in spring 2026, establishing a new regulated market that clinicians will need to understand for patient recommendations and treatment protocols.
Cannabis compounds CBD and CBG may help reverse fatty liver disease, study finds
Summary for Cannabis Clinician
CBD and CBG demonstrate potential therapeutic effects against hepatic steatosis, expanding the evidence base for cannabinoid applications in metabolic disease management.
From Billion-Dollar Hemp Drinks to FDA Cease-and-Desist Letters: The Cannabis Industry’s …
Summary
This article examines regulatory enforcement actions against cannabis beverage companies, illustrating the regulatory compliance challenges clinicians must understand when advising patients about commercially available cannabinoid products.
Cannabis Compounds CBD and CBG Show Promise in Reducing Liver Fat and Improving …
Summary
Cannabis cannabinoids CBD and CBG demonstrate potential therapeutic effects on hepatic steatosis and metabolic markers, offering clinicians evidence-based options for patients with fatty liver disease.
New Cannabis Group Will Help Ground Policy In Science And Patient Experience As …
I’d be happy to help, but the article summary appears to be missing. Could you please provide the summary text so I can write an accurate, factual sentence for cannabis clinicians?
New Top Cannabis Regulator Sets Priorities In First Board Meeting
Summary
A new cannabis regulator outlined enforcement and oversight priorities in their initial board meeting, affecting clinical practice standards and compliance requirements for healthcare providers.
Brazil’s Cannabis Crossroads: New Rules, Old Truths, and the Road Ahead
Summary Sentence
Brazil’s evolving cannabis regulations, clinical applications, and implementation challenges relevant to healthcare providers prescribing cannabis-based treatments in the region.
2 Greater Cincinnati breweries file lawsuit over Ohio ban on THC beverages – WLWT
Summary
Two Greater Cincinnati breweries are challenging Ohio’s prohibition on THC-infused beverages through legal action, affecting regulatory compliance and product development for cannabis-containing drink manufacturers.
New Ohio law means THC-infused drinks won’t be available on many store shelves – WTVG
Summary
Ohio’s new law restricts THC-infused beverage distribution in retail settings, affecting product accessibility and clinical considerations for cannabinoid dosing and patient recommendations.
Lawmakers strike down bill capping THC levels in Oregon’s cannabis edibles – Yahoo
One-Sentence Summary
Oregon lawmakers rejected legislation that would have limited THC concentrations in cannabis edibles, preserving current product potency standards relevant to clinician dosing recommendations.
Attempt to limit potency of THC in marijuana edibles fails at Oregon Legislature
Cannabis Article Summary
Oregon legislators failed to pass legislation limiting THC potency in marijuana edibles, affecting clinical dosing standardization and patient safety considerations for medical cannabis practitioners.
Cannabis Compounds CBD and CBG Slash Liver Fat and Restore Metabolic Health
Summary
CBD and CBG cannabinoids reduced hepatic steatosis and improved metabolic markers in research, providing clinicians evidence-based data for potential therapeutic applications in metabolic liver disease management.
Cannabinoid Oral Mucosal Delivery: Approaches to Formulation, Fabrication, and … – PubMed
Cannabinoid Oral Mucosal Delivery
This article examines formulation and fabrication approaches for delivering cannabinoids through oral mucosal tissues, relevant to clinicians developing non-inhalation cannabis therapeutics.
Study: CBD-Dominant Cannabis Products Provide Significant Anxiety Relief – NORML
Summary
CBD-dominant cannabis products demonstrated significant anxiolytic effects in clinical research, providing clinicians with evidence-based data for treating anxiety disorders in patient populations.
Clinical Trial: Cannabis Extracts Significantly Reduce Myofascial Pain – NORML
Summary
A clinical trial demonstrates cannabis extracts’ efficacy in reducing myofascial pain, providing clinicians evidence-based data for therapeutic applications in musculoskeletal pain management.
As a Medical Cannabis Patient, I’m Watching This Supreme Court Case Closely
I’d be happy to help, but the article content wasn’t provided—only the title and an empty summary section. Could you share the article text or additional details about which Supreme Court case is being discussed?
The Week in Weed: March 2026 | Seyfarth Shaw LLP – JDSupra
Summary
This article covers weekly cannabis legal and regulatory updates relevant to healthcare professionals managing patient care within evolving state and federal frameworks.
Marijuana gummies sold in Ohio recalled. Why, where they were sold – The Columbus Dispatch
Summary
Marijuana gummies sold in Ohio were recalled, likely due to safety or quality control issues—relevant for clinicians counseling patients on product safety and regulatory compliance.
New Group Launches Ahead of Medicare CBD Pilots – Cannabis Wire
Summary
A new organization is forming to prepare for upcoming Medicare pilots testing cannabidiol (CBD) in clinical settings, potentially expanding insurance coverage and clinical applications for cannabis medicine.
Marijuana Status Based Prohibition Tag Archives – Powers Law Firm PA
Cannabis Article Summary
This resource covers legal prohibition frameworks affecting marijuana status, relevant for clinicians navigating regulatory compliance and patient care within varying jurisdictional cannabis restrictions.
Louisiana lawmaker files bill to legalize recreational marijuana through licensed dispensaries
Summary
Louisiana legislator proposes regulatory framework for legal recreational cannabis sales, directly affecting clinician prescribing practices and patient access pathways.
Mom’s homemade medical cannabis recipe now being sold at Georgia dispensaries
Summary
A mother’s medical cannabis formulation developed for personal use has entered commercial distribution through Georgia dispensaries, demonstrating patient-derived product innovation in regulated cannabis markets.
Ohio THC drink ban draws lawsuit from Cincinnati breweries
Summary
Ohio’s THC beverage restrictions face legal challenge from breweries, affecting cannabinoid product regulation and clinical access to cannabis-infused beverage options.
Israeli researchers find cannabis compounds could lead to 1st drug for fatty liver disease
Summary
Israeli researchers identified cannabis compounds as potential treatment for fatty liver disease, offering clinicians a new therapeutic option for a prevalent condition currently lacking FDA-approved medications.
Virginia adult-use sales bills pass both chambers, head to conference committee! – Blog
Summary
Virginia’s legislature passed adult-use cannabis sales bills through both chambers, requiring reconciliation in conference committee before potential legalization—affecting prescribing practices and patient access pathways for clinicians.
Study highlights pros, cons of medical marijuana as its future in Tennessee remains unknown
Summary
This article examines medical marijuana’s potential benefits and drawbacks while discussing uncertain regulatory prospects in Tennessee, relevant for clinicians evaluating treatment options.
(Word count: 24)
2026 Utah legislature on cannabis, psychedelics and kratom – Fox 13
Cannabis Clinician Summary
The 2026 Utah legislature addresses regulatory and legal developments affecting cannabis, psychedelics, and kratom—directly impacting clinical practice, patient access, and prescribing guidelines in Utah.
Oregon Bill To Ban Marijuana Edibles With More Than 10 Milligrams Of THC Fails
Summary
Oregon’s proposed legislation to limit THC content in cannabis edibles to 10mg per serving failed, maintaining current higher dosing limits that clinicians must consider when counseling patients on safe consumption.
Georgia bill could limit probable cause for smell of marijuana, cannabis, or hemp – YouTube
One-Sentence Summary
Georgia legislation proposes restricting law enforcement’s ability to establish probable cause based solely on marijuana odor, affecting patient legal protections and clinician documentation practices.
Study reveals cannabis compounds reduce threat of fatty liver disease | Health
Response
Cannabis clinicians should understand this study’s findings on cannabinoid effects on hepatic lipid accumulation, as it provides clinical evidence relevant to patient counseling regarding metabolic health outcomes.
Prescription Cannabidiol CBD Oil Market to Hit US$ 190.9 Billion by 2032 at 23.48% CAGR
One-Sentence Summary
Prescription CBD oil market is projected to reach $190.9 billion by 2032 with 23.48% annual growth, indicating expanding clinical demand and investment in cannabinoid-based therapeutics.
I’d be happy to help, but I don’t see the article content provided. Could you please share the full text or details from the TPS Cannabis News – StratCann article so I can write an accurate summary for cannabis clinicians?
InMed Pharmaceuticals Shifts Focus to Therapeutic Programs, Ends BayMedica’s Non …
Summary
InMed Pharmaceuticals discontinued its non-exclusive distribution agreement with BayMedica, refocusing on developing cannabis-derived therapeutic programs with potential clinical applications.
Cannabis Extracts Significantly Reduce Myofascial Pain | Trending – Labroots
Summary
Cannabis extracts demonstrate clinical efficacy in reducing myofascial pain, providing clinicians evidence-based data for patient treatment protocols and therapeutic applications.
Pediatricians warn about cannabis use disorder, kids’ easy access to the drug – YouTube
Summary
Pediatricians highlight cannabis use disorder in children and accessibility issues, which are clinically relevant for understanding adolescent risk factors and treatment considerations in cannabis medicine practice.
West Virginia House Passes Bill To Allocate Medical Marijuana Revenue, With Some …
Cannabis Article Summary
West Virginia legislature advanced a bill distributing medical marijuana tax revenue, affecting funding availability and regulatory oversight relevant to clinical cannabis practice in the state.
Study highlights positive, negatives of medical marijuana – WKRN News 2
Summary
A study examining both therapeutic benefits and adverse effects of medical marijuana provides clinical evidence relevant to patient treatment decisions and risk-benefit assessments.
The science behind roadside THC testing and diving into SGI’s zero-tolerance policy – Global News
Cannabis Clinician Summary
This article examines roadside THC testing methods and Saskatchewan Government Insurance’s zero-tolerance driving policy, relevant to clinicians assessing impairment and patient safety counseling.
Mom’s homemade medical cannabis recipe now being sold at Georgia dispensaries
Summary
A Georgia resident’s homemade medical cannabis formulation has entered commercial dispensary distribution, demonstrating patient-developed protocols moving into regulated retail settings.
‘Pot for Potholes Act’ aims to legalize marijuana in Tennessee and distribute taxes to repair …
Summary
Tennessee legislation proposes legalizing marijuana and dedicating tax revenue to infrastructure repair, creating potential patient access changes and clinical practice implications for healthcare providers.
One of Colorado’s Largest Dispensary Chains Agrees to Buyout – Denver Westword
Summary
A major Colorado dispensary chain’s acquisition indicates consolidation in the legal cannabis retail market, which may affect product availability, pricing, and patient access patterns that clinicians should monitor.
Cannabis legalization driving increases in marijuana use among US adults with historically … – MSN
Cannabis Legalization and Adult Use Patterns
This article examines how cannabis legalization correlates with increased marijuana consumption among US adults in historically marginalized populations, relevant for clinicians treating this demographic.
Ohio Department of Commerce recalls certain marijuana gummies lacking THC symbol … – Facebook
Summary
Ohio’s Department of Commerce recalled marijuana gummies missing required THC labeling symbols, ensuring clinicians can accurately verify product potency and compliance for patient recommendations.
Perceptions of the relative harmfulness of marijuana and alcohol among adults in Oregon.
Summary
This study examines how Oregon adults perceive marijuana versus alcohol safety, providing clinicians evidence on patient beliefs that may influence treatment discussions and health recommendations.
What’s Really Happening With Cannabis ETF MSOS? – The Dales Report
Summary
This article analyzes the Marijuana ETF (MSOS), which tracks cannabis industry stocks and may affect investment portfolios of cannabis professionals and stakeholders.
Study reveals cannabis compounds reduce threat of fatty liver disease – Daily Journal
Summary
Cannabis compounds show potential to reduce fatty liver disease risk, providing clinicians evidence-based information for patient consultations about hepatic health outcomes.
Scientists are raising new concerns about marijuana use in teens – KPBS
This article reviews evidence linking adolescent cannabis use to psychiatric risks including psychosis, depression, and anxiety, relevant to clinicians assessing developmental vulnerability in teen patients.
Clinical Trial: Cannabis Extracts Significantly Reduce Myofascial Pain – NORML
Cannabis extracts administered sublingually reduced myofascial pain in temporomandibular disorder patients, expanding treatment options for conditions unresponsive to conventional medications.
Can the placenta predict schizophrenia risk? Lessons from prenatal cannabis exposure
Cannabis Clinician Summary
Research investigates whether placental biomarkers can identify schizophrenia risk from prenatal THC exposure, informing clinical counseling on cannabis use during pregnancy.
Scientists are raising new concerns about marijuana use in teens – YouTube
Summary
Adolescent cannabis use poses clinical risks because THC exposure during brain development (through mid-twenties) correlates with disrupted outcomes, making age-related vulnerability a key consideration for cannabis clinicians.
A huge study finds a link between cannabis use in teens and psychosis later – NPR
This study documents the association between adolescent cannabis use and later psychosis risk, informing clinical screening and counseling practices for young patients.
Teen Cannabis Use Tied to Increase in Serious Mental Illness – Medscape
Adolescent cannabis use during critical brain development periods is associated with increased risk for psychotic and bipolar disorders, which clinicians should consider when assessing young patients.
Brain Researchers Finally Know Why Cannabis Use Increases Appetite – The Debrief
Summary for Cannabis Clinician
Researchers identified the neurological mechanisms by which cannabinoids stimulate appetite, providing clinicians with evidence-based understanding of “the munchies” for therapeutic applications.
Teen Marijuana Use Doubles Chances of Future Psychotic Disorders, Study Finds
Adolescent cannabis use is associated with increased risk of adult psychotic disorders, which clinicians should consider when assessing patient history and providing preventive counseling to at-risk youth.
The association between cannabis use and brain reward anticipation: a 12-month … – Nature
One-Sentence Summary
This research examines how cannabis use affects brain reward processing, a critical area for clinicians assessing addiction risk, motivation changes, and treatment planning in cannabis users.
THC levels in blood and urine are “unreliable” indicators of driving impairment – leafie
THC blood/urine levels don’t reliably predict driving impairment due to THC’s lipophilic properties, requiring clinicians to assess impairment through alternative methods rather than relying on biomarker thresholds.
Study Links Prenatal Cannabis Exposure To Schizophrenia – New Telegraph
Prenatal cannabis exposure may create placental biomarkers associated with increased schizophrenia risk in offspring, informing clinical counseling for pregnant patients considering cannabis use.
The Endocannabinoid System’s Contribution to Placebo Analgesia – bioRxiv
Summary for Cannabis Clinicians
The endocannabinoid system mediates placebo analgesia, meaning expectation-driven pain relief uses cannabinoid signaling pathways similar to cannabis therapeutics, potentially explaining treatment efficacy mechanisms.
Modulating the endocannabinoid system in alcohol use disorder: A translational systematic …
Summary for Cannabis Clinicians
This article examines how modulating cannabinoid receptors (CB1/CB2) and endocannabinoids may address neurobiological dysfunctions—reward processing, stress response, impulse control—underlying alcohol use disorder.
Cannabis hyperemesis syndrome is on the rise: What symptoms to watch for – The Hill
Cannabis hyperemesis syndrome causes severe cyclic nausea and vomiting in chronic heavy users; clinicians must recognize it to avoid prolonged misdiagnosis and unnecessary investigations.
Association of Cannabis Use Disorder Versus Other Substance Use Disorders … – Psychiatry Online
One-Sentence Summary
This research compares psychiatric burden across substance use disorders to help clinicians understand cannabis use disorder’s clinical impact amid changing legal landscapes.
Study Shows Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia …
Cannabis and Cognition
This study examines whether lifetime cannabis use correlates with cognitive decline or dementia risk in older adults, informing clinicians’ risk assessment and patient counseling on long-term cognitive safety.
Study Finds No Link Between Lifetime Cannabis Use and Cognitive Decline in Older Adults
Cannabis Clinician Summary
This research suggests lifetime cannabis use does not accelerate cognitive decline in older adults, which is clinically relevant given the increasing number of elderly patients accessing cannabis treatment.
Israeli researchers find cannabis compounds could lead to 1st drug for fatty liver disease
Israeli researchers identified cannabinoid compounds effective against non-alcoholic fatty liver disease, potentially offering the first pharmaceutical treatment for a condition affecting hundreds of millions globally.
The Coming Divide in Cannabis: Why the U.S. Market Remains Out of Reach for Global Operators
Summary Sentence
The article examines barriers preventing international cannabis operators from entering the U.S. market, relevant to clinicians navigating evolving regulatory landscapes affecting product availability and sourcing.
North Shore Dispensary opens in Duluth’s Lincoln Park – WDIO.com
A cannabis dispensary opened in Duluth’s Lincoln Park neighborhood, representing local retail expansion that clinicians should monitor for patient access and community health implications.
Study reveals cannabis compounds reduce threat of fatty liver disease | Health – News-Topic
Cannabis Clinician Summary
Cannabinoids may reduce non-alcoholic fatty liver disease risk through anti-inflammatory and metabolic mechanisms, potentially offering therapeutic applications for hepatic health in clinical practice.
Observational study on medical marijuana use seeks Arizona participants – KJZZ
Cannabis Research Recruitment Summary
This article describes an observational study recruiting Arizona participants to generate real-world evidence on medical cannabis use across diverse patient conditions and consumption methods.
Cannabis compounds show promise in fighting fatty liver disease, scientists say – AZERTAC
Cannabis Research Summary
Non-psychoactive cannabinoids CBD and CBG show preclinical evidence of reducing hepatic fat accumulation through endocannabinoid receptor interactions, offering potential therapeutic targets for fatty liver disease management.
A huge study finds a link between cannabis use in teens and psychosis later – KUOW
Longitudinal research demonstrates that adolescent cannabis use correlates with increased psychosis risk in adulthood, informing clinical assessment and patient counseling on developmental vulnerability.
Prescribed cannabis and driving behaviours among two samples of people who regularly … – UNSW
Medical cannabis and driving safety
This research examines how THC impacts driving ability, addressing clinicians’ need to counsel patients on impairment risk and timing of vehicle operation.
Cannabis research: India to start human trials for medicinal marijuana – NewsBytes
India is launching human clinical trials for medicinal cannabis, providing clinicians with controlled safety and efficacy data needed to support evidence-based prescribing practices in a traditionally restrictive regulatory environment.
Cannabis Munchies Driven by Brain Reward Signals | Technology Networks
Cannabis Munchies and Brain Reward Circuits
This research elucidates the neurological mechanisms underlying cannabis-induced increased appetite, providing clinicians evidence-based understanding to better counsel patients on this common side effect.
The association between cannabis use and brain reward anticipation: a 12-month … – Nature
This study examines how THC affects reward anticipation in the developing brain over 12 months, relevant to clinicians assessing cannabis-related neurobiological changes in adolescent and young adult patients.
Screaming, vomiting, and daily weed: The rise of ‘scromiting’ among chronic cannabis users
Cannabinoid hyperemesis syndrome causes severe cyclical nausea and vomiting in chronic cannabis users, requiring clinicians to recognize this paradoxical adverse effect when treating heavy users.
Study finds no links between cannabis use and cognitive decline or dementia in older people
This article reports research findings that challenge the assumption cannabis use causes cognitive decline or dementia in older adults, relevant to clinical risk assessment and patient counseling.
Cannabis Use and Brain Aging: What a Major Study Reveals – Born2Invest
This article examines cannabis use’s association with brain aging trajectories using large datasets, providing clinicians evidence-based information relevant to patient counseling and risk assessment.
Cannabis use not linked to cognitive decline or dementia in older adults, study finds – leafie
Summary for Cannabis Clinician
This study challenges the assumption that cannabis use causes cognitive decline or dementia in older adults, providing evidence-based reassurance for clinicians treating elderly patients.
Study reveals cannabis compounds reduce threat of fatty liver disease | Health – WFMZ.com
Summary for Cannabis Clinician
Preclinical research indicates CBD and THC may reduce hepatic fat and inflammation in metabolic-associated steatotic liver disease, expanding potential therapeutic applications beyond current uses.
Placental Changes From Prenatal Cannabis Exposure Could Flag Higher Schizophrenia …
Summary for Cannabis Clinicians
Prenatal cannabis exposure causes epigenetic and gene expression changes in placental tissue linked to neurodevelopmental disorders like schizophrenia, providing a biological marker for identifying at-risk pregnancies.
Teens Who Use Cannabis Face Higher Risk Of Mental Disorders, Study Finds – Forbes
Adolescent cannabis use correlates with increased psychiatric disorder risk, informing clinicians’ need for early prevention strategies and monitoring during brain development.
A huge study finds a link between cannabis use in teens and psychosis later – WBAA
Cannabis Clinician Summary
Large-scale study links adolescent cannabis use to increased psychosis and depression risk in adulthood, supporting clinical guidance against teen use during critical brain development.
Researcher: Remediated cannabis may still have harmful mold – MJBizDaily
Cannabis remediation may not eliminate all harmful molds, potentially exposing immunocompromised patients to fungal risks despite passing state testing requirements.
So, What Does an Adult at Low Risk of Cannabis Dependence Look Like?
This article examines risk factors for cannabis dependence in adults, helping clinicians identify patients who can safely use cannabis therapeutically with lower dependence risk.
Cannabis hyperemesis syndrome cases surge in Virginia ERs – YouTube
Cannabis hyperemesis syndrome is increasing in Virginia emergency departments, presenting clinicians with a real condition causing cyclical vomiting and abdominal pain in frequent users requiring clinical recognition.
Study Finds Veterans With SUD Used Cannabis to Alleviate Pain, Anxiety, and Improve Poor …
Veterans with SUD reported using cannabis to manage pain, anxiety, and sleep during non-cannabis SUD treatment, clinically relevant information for treating this population.
ARTELO BIOSCIENCES, INC. SEC 10-K Report – TradingView
Summary for Cannabis Clinician
Artelo Biosciences develops targeted cannabinoid therapies for cancer-related conditions, representing pharmaceutical-grade drug development moving beyond whole-plant cannabis products.
Bill to protect Nebraska physicians recommending medical cannabis advances to floor
Summary for Cannabis Clinician
Nebraska legislation protects physicians from licensing board penalties when recommending medical cannabis, removing a significant barrier to patient access.
Associations of cannabis use, other substances, and lifestyle choices on anxiety in medical …
This article examines how cannabis use interacts with alcohol, caffeine, exercise, and sleep to affect anxiety outcomes in medical patients, informing clinician treatment decisions.
Nebraska bill to protect healthcare practitioners who recommend medical cannabis sails out of com…
Cannabis Clinician Summary
Nebraska legislation protects healthcare practitioners recommending medical cannabis, addressing legal liability concerns that arise when state voter-approved programs lack physician safeguards.
Major study finds strong link between cannabis, anxiety and depression – Medical Xpress
This research documents associations between cannabis use and anxiety/depression while highlighting the challenge of determining causation—critical for clinicians assessing patient outcomes and treatment planning.
Research: Munchies May Aid Those Lacking Appetite – Pullman Today
Cannabis activates CB1 receptors in hunger-regulating brain regions, stimulating appetite—clinically relevant for treating patients with appetite loss from disease or medication.
President Biden Signs Historic Cannabis Research Bill – Ganjapreneur
Summary
President Biden signed a federal bill removing research barriers for cannabis studies, enabling clinicians to conduct rigorous clinical investigations into cannabinoids more efficiently.
Marijuana Use & Dangers for Adolescents & Young Adults
This article examines cannabis use risks during adolescence and young adulthood, focusing on THC’s neurological effects during critical brain development—essential knowledge for clinicians treating this vulnerable population.
Cannabis hyperemesis syndrome is on the rise: What symptoms to watch for – KGET.com
Cannabis hyperemesis syndrome causes severe nausea and vomiting in chronic heavy users, requiring clinicians to recognize this paradoxical adverse effect when treating cannabis patients.
Study Published in Pediatrics Finds Infrequent Cannabis Use Can Impact Adolescent …
Adolescent cannabis use at low frequencies (monthly or less) correlates with academic decline and neurodevelopmental disruption, informing clinical risk assessment and counseling during patient evaluations.
Pipeline Progress Drives Investor Focus at Agentix – Ad-hoc-news.de
Pharmaceutical companies are developing targeted cannabinoid drugs that modulate specific receptor pathways, offering clinicians more precise treatment options beyond whole-plant cannabis.
Study: Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia Risk in … – NORML
Summary for Cannabis Clinician
This article reports longitudinal research findings on whether lifetime cannabis use is associated with cognitive decline or dementia risk in older adults, informing clinical counseling about long-term neurological safety.
Study: CBD-Dominant Cannabis Products Provide Significant Anxiety Relief – NORML
CBD-dominant cannabis products show clinical promise for anxiety treatment, relevant to clinicians evaluating cannabinoid-based therapeutic options for symptom management.
Toronto police shutdown multiple unlicensed cannabis dispensaries – CP24
Summary
Toronto police closed unlicensed cannabis dispensaries, affecting supply chain integrity and patient access to regulated, quality-assured products that clinicians recommend.
Using cannabis to cut back on alcohol? Your working memory might dictate if it works
Summary
This article examines how working memory capacity may influence whether cannabis use helps individuals reduce alcohol consumption, a finding relevant to clinical assessment and patient outcomes.
Kentucky bill would change how alcohol, cannabis beverages are taxed – WKYT
Summary
Kentucky proposed legislation aims to align taxation structures between alcoholic and cannabis beverages, potentially affecting product pricing, market accessibility, and clinical patient recommendations.
Mom’s homemade medical cannabis recipe now being sold at Georgia dispensaries – WALB
Summary
A Georgia mother’s homemade medical cannabis formulation has gained commercial distribution through state dispensaries, potentially demonstrating patient-developed therapeutic approaches entering regulated markets.
Teens Didn’t Just Discover Weed. So Why Is The Wall St. Journal Acting Like They Did?
The article critiques media sensationalism around teen cannabis use, relevant for clinicians who need accurate epidemiological data to inform patient education and clinical risk assessments.
Exploring the Growing Trust in Cannabidiol Oil – The Assam Tribune
Summary
This article examines increasing clinical and public confidence in cannabidiol (CBD) oil as a therapeutic agent, relevant to clinicians evaluating CBD’s evidence base and patient applications.
Cannabis payouts drop for most Oakland County communities
Summary
Oakland County cannabis communities received reduced tax revenue payouts, affecting funding available for local cannabis regulation and licensing infrastructure that clinicians rely on.
New Cannabis Dispensary Opens On Route 22 In Somerville | Bridgewater, NJ Patch
A cannabis dispensary opened on Route 22 in Somerville, expanding retail access in the New Jersey area and potentially increasing patient convenience for obtaining cannabis products.
Cannabis use by teenagers doubles their risk of developing psychotic and bipolar disorders
Summary Sentence
Cannabis use in teenagers is associated with doubled risk of psychotic and bipolar disorders, which clinicians must assess when evaluating adolescent patients and providing risk counseling.
Pediatricians warn about cannabis use disorder, kids’ easy access to the drug
Summary
Pediatricians are warning about cannabis use disorder in children and their access to the drug—critical for clinicians treating youth and adolescent cannabis dependence.
Teen Cannabis Use May Double Your Risk of Psychosis and Bipolar
Adolescent cannabis use carries elevated risks for psychosis and bipolar disorder compared to adult use, which clinicians must consider when assessing psychiatric vulnerability in younger patients.
Can You Drive the Next Morning After Weed? Study Finds No Significant Impairment 12–15 …
Summary for Cannabis Clinicians
This article examines next-day driving safety after cannabis use, addressing a clinically relevant question about impairment timing, individual variability in THC metabolism, and tolerance effects.
Medicare may soon cover certain cannabis medications for seniors – MSU Denver RED
Medicare’s potential coverage of cannabis-based medications expands access to cannabinoid therapeutics for seniors with chronic pain, sleep disorders, and neuropathic conditions, affecting clinical practice and patient populations.
Placenta May Hide Early Warning Signs of Schizophrenia Risk – ScienceAlert
One-Sentence Summary
Prenatal THC exposure may create detectable placental biomarkers associated with schizophrenia risk, relevant for clinicians counseling pregnant patients about cannabis use.
Bridging the Gap: Medical Cannabis, Regulators, and the Reality of Clinical Accountability
Medical Cannabis Accountability Standards
This article addresses the regulatory and professional standards governing medical cannabis prescribing, emphasizing that clinicians must maintain documentation and safety practices equivalent to conventional medicine.
Cannabis use, anxiety and depression are all on the rise in Canada: study – CTV News
This study documents concurrent increases in Canadian cannabis use, anxiety, and depression, providing clinicians with epidemiological data relevant to assessing mental health risk factors in cannabis-using patients.
A Prescription Digital Therapeutic Framework for Enhancing Medical Cannabis Care
Digital Therapeutics in Medical Cannabis Care
This article examines prescription digital tools for medical cannabis treatment, emphasizing their role in enabling outcome measurement, personalized dosing, and evidence-based clinical protocols.
Ananda Pharma to Begin Dosing in NHS-Backed CBD Endometriosis Trial
One-Sentence Summary
Ananda Pharma is conducting an NHS-backed clinical trial of CBD for endometriosis pain management, addressing an undertreated chronic condition affecting millions of women.
Washington Senators Approve Bill To Let Terminally Ill Patients Use Medical Cannabis In Hospitals
Washington legislation permits terminally ill patients to use medical cannabis in hospitals, bridging the gap between state law and facility policies that previously prohibited such use.
Natural Neuroprotection: Exploring the Potential of Non-Psychoactive Cannabinoids
Summary for Cannabis Clinicians
This article examines how non-psychoactive cannabinoids (CBD, CBG, CBDV) may protect neurons by modulating inflammation and oxidative stress through endocannabinoid system pathways relevant to neurodegenerative diseases.
America Doesn’t Have A ‘Marijuana Problem,’ As NYT Claims—It Has a Cannabis Education …
This article critiques media framing of cannabis risks and identifies gaps in medical education and research access as core issues clinicians face when treating patients with cannabis therapeutics.
Are My THC Gummies Going Away? – Science Friday
Summary for Cannabis Clinician
Federal scrutiny of hemp-derived THC gummies may affect patient access to products currently relied upon for clinical use, creating potential supply and legal uncertainty.
House panel approves proposed medical cannabis law – POLITIKO
The Philippine House approved medical cannabis legislation establishing regulated research infrastructure and patient access pathways, expanding treatment options in a previously restrictive regulatory environment.
What effects does THC have on youth who dabble? – YouTube
This article examines THC’s impact on adolescent brain development during critical neurodevelopmental periods, particularly in the prefrontal cortex and limbic system—essential knowledge for clinicians assessing developmental risks in young cannabis users.
Tennessee sisters fear new hemp law as CBD oils become harder to access – YouTube
Summary for Cannabis Clinician
Tennessee’s new hemp law restricts CBD oil access for patients with dystonia who have found therapeutic benefit from full-spectrum formulations, limiting treatment options for neurological movement disorders.
“Mother of Cannabinoids”: The Rising Potential of CBG and CBG-A – Cannabis Health News
One-Sentence Summary
This article examines CBG and CBGA’s emerging clinical potential for anxiety, memory, and anti-cancer applications, important for clinicians evaluating cannabinoid treatment options beyond THC and CBD.
Ghana launches medicinal cannabis programme under strict regulation
Ghana’s medicinal cannabis regulatory framework enables structured research for clinical evidence generation, establishing West Africa’s first formal pathway for cannabis-based medical practice and treatment protocols.
Patient Protect launches to tackle discrimination against UK medical cannabis patients
Summary Sentence
Medical cannabis patients in the UK face discrimination in housing, employment, law enforcement, and driving assessments, requiring clinicians to understand systemic barriers affecting patient welfare beyond clinical outcomes.
Study Links Rising Cannabis Use to Poor Mental Health – U.S. News & World Report
This research examines cannabis use’s impact on mental health in older adults, informing clinical treatment approaches for a population with complex substance-metabolism interactions.
Natural Approaches to Managing Chronic Inflammation – WorldHealth.net
Summary for Cannabis Clinician
This article explains how phytocannabinoids interact with the endocannabinoid system to modulate inflammation and immune response, which is relevant for clinical applications in managing inflammatory conditions.
Alabama medical cannabis program is now accepting patient registrations! – Blog
Alabama’s new medical cannabis program enables patient registration for qualifying conditions like chronic pain and PTSD, expanding clinical access in a traditionally restrictive state.
House panel revives medical cannabis bill – Daily Tribune
The Philippines is establishing a regulated medical cannabis framework through approved House legislation, directly impacting clinical practice and patient access in a historically restrictive jurisdiction.
More Kentucky children dying to ‘preventable’ overdoses, new report shows
This article reports increased pediatric cannabinoid overdoses in Kentucky, emphasizing the clinical importance of safe storage counseling and childproof packaging to prevent accidental pediatric exposure.
Legislation on medical cannabis: DOH bares conditions – Cebu Daily News
The Philippines Department of Health is establishing regulatory conditions for medical cannabis legalization based on clinical and scientific evidence, affecting legal prescribing frameworks for clinicians.
Sober shift could reshape spending, but doctor warns THC may be the new vice – Fox Baltimore
This article examines the public health implications of declining alcohol use coupled with rising cannabis/THC consumption, relevant to clinicians assessing patient substance use patterns and health outcomes.
Secondhand marijuana smoke has fine particles that can cause asthma attacks and … – Instagram
Secondhand marijuana smoke contains fine particulate matter that triggers respiratory inflammation and asthma exacerbation, informing clinician counseling on patient exposure risks.
Nebraska’s Medical Cannabis Commission holds hearing on emergency regulations – KETV
Nebraska’s medical cannabis commission set a 90-day possession limit of 5 grams—below therapeutic dosing levels for most conditions—affecting patient access and clinical treatment planning.
Nebraska Bill Seeks To Shield Doctors Recommending Medical Cannabis From Arrest
Nebraska legislation would shield physicians recommending medical cannabis from arrest, enabling doctors to practice clinical medicine without criminal liability concerns.
The Week in Weed: February 27, 2026 – Lexology
Summary for Cannabis Clinician
Recent research documents measurable physiological and psychoactive responses to acute cannabis use, providing clinicians with evidence-based data for patient assessment and treatment planning.
First-of-its-kind long-term study at Virginia Tech shares how cannabis use can affect driving
Cannabis and Driving Study
This Virginia Tech research examines how THC impairs driving performance through non-linear dose effects, providing clinicians with evidence-based information for patient counseling on cannabis use and transportation safety.
Expert breaks down hidden dangers of doctors prescribing medical marijuana – UNILAD
This article examines Cannabis Use Disorder prevalence rates among medical marijuana users and discusses physician prescribing concerns in medicalized cannabis contexts.
Hemp article tells us why WI needs government regulations | Letter – Milwaukee Journal Sentinel
Hemp-derived cannabis products lack testing and labeling regulations that licensed dispensaries require, potentially exposing patients to undisclosed THC levels affecting clinical outcomes.
Campaign Launched in Memory of Mum Who Helped Change UK Medical Cannabis Law
This article covers medical cannabis use for drug-resistant childhood epilepsy, specifically Dravet and Lennox-Gastaut syndromes, where cannabidiol has demonstrated clinical efficacy in reducing seizures.
New Cannabis Group Will Help Ground Policy In Science And Patient Experience As …
A new cannabis medicine group aims to ground federal cannabinoid policy in scientific evidence and patient experience during ongoing rescheduling discussions.
Hey Sonar: Rethinking your relationship with weed – CSU Signal
I cannot write an accurate summary without access to the article’s content. Please provide the article text or key details so I can create a factual one-sentence description relevant to cannabis clinicians.
‘Green lab’ helps Oregon officers recognize marijuana-impaired driving | The Astorian
Oregon law enforcement training on cannabis impairment detection
This article covers how Oregon police are being trained to recognize marijuana-impaired driving through a “green lab” program, which is relevant to clinicians treating cannabis users and understanding impairment assessment standards.
Medical marijuana as someone working in healthcare industry : r/florida – Reddit
Summary
This Reddit discussion addresses healthcare workers’ considerations regarding medical marijuana use and workplace implications in Florida, relevant to clinical decision-making and professional guidelines.
Medical and recreational marijuana bills introduced in Kansas Legislature – KAKE
Kansas Legislature is considering medical and recreational cannabis bills, potentially enabling legal patient access in a state currently prohibiting all cannabis use.
Study highlights pros, cons of medical marijuana as its future in Tennessee remains unknown
Medical Cannabis in Tennessee
Medical cannabis legislation in Tennessee faces evolving political support amid federal policy shifts, directly affecting clinicians’ ability to recommend evidence-based cannabis treatments to patients.
The House Committee on Dangerous Drugs, together with the Committee on Health … – Facebook
The Philippine House is developing medical cannabis legislation with regulatory framework and research provisions, directly impacting clinical practice protocols and patient access for qualified healthcare providers.
Health advocate underscores ‘real danger’ in medical cannabis legalization in PH
Cannabis Clinician Summary
This article examines Philippine regulatory and healthcare infrastructure concerns regarding medical cannabis implementation, directly impacting clinical practice standards and patient access frameworks.
Extended moratorium on Oklahoma medical marijuana business licenses approved by House
Oklahoma’s House approved an extended moratorium on new medical marijuana licenses due to market oversaturation, which affects clinicians’ access to regulated product variety and supply chain reliability.
MS Senate committee approves one medical marijuana bill, rejects another
Summary Sentence
Mississippi’s legislature is debating medical cannabis program expansion, specifically addressing patient eligibility criteria and clinical administration settings—directly affecting practitioners’ ability to recommend and deliver cannabis therapeutically.
Major Canadian Study Reveals Significant Connection Between Cannabis Use, – Bioengineer.org
Summary for Cannabis Clinician
This research documents the bidirectional relationship between cannabis use and mood disorders, highlighting the need for clinicians to assess both causation and symptom management when treating patients.
DOSE) (OTCQB: RDTCF) Advances QuickStrip™ Research Backed by NFL … – StreetInsider
Summary for Cannabis Clinician
QuickStrip™ sublingual/buccal thin-film technology bypasses hepatic metabolism, enabling faster onset and more consistent CBD absorption compared to conventional oral formats.
420 with CNW – Texas Grapples with Increasing Cases of Marijuana DUI
Cannabis DUI: Clinical Relevance
This article addresses cannabis-impaired driving safety and the absence of validated THC blood thresholds, which directly impacts how clinicians counsel patients on driving safety and legal risks.
Recreational Marijuana – Cons | Britannica
Summary
This article examines the pharmacological interaction between cannabis and alcohol, including research on how THC may influence alcohol consumption patterns—relevant for clinicians assessing patient substance use and potential therapeutic applications.
Feds warn about medical cannabis & hemp in drug tests (Newsletter: March 6, 2026)
Federal agencies are warning that drug tests cannot reliably distinguish between legal hemp-derived CBD and medical cannabis, complicating employment and legal outcomes for patients.
Recreational Marijuana – Cons | Britannica
Summary
This Britannica article examines documented drawbacks of recreational marijuana legalization, providing clinicians evidence-based information on potential public health risks relevant to patient counseling and clinical decision-making.
These Maine towns have the most cannabis businesses – The County
Summary Sentence
This article identifies Maine towns with the highest concentration of cannabis businesses, providing clinicians with geographic data on local market saturation and accessibility patterns relevant to patient care discussions.
DOH sets conditions on proposed medical cannabis legalization | Philippine News Agency
The Philippines’ Department of Health is establishing regulatory conditions for medical cannabis legalization, including patient access pathways and research oversight—critical for clinicians seeking formal practice guidelines.
Building a global standard for cannabis vapes one terpene at a time – MJBizDaily
Summary for Cannabis Clinician
This article addresses standardization of terpene profiles in cannabis vape products, relevant to clinicians because terpenes may modulate therapeutic effects through interactions with cannabinoids.
Cooney introduces bill to allow selling of low-potency cannabis beverages at liquor and wine stores
Low-THC beverages present distinct absorption and onset patterns compared to inhalation methods, requiring clinicians to provide different dosing and timing guidance to patients.
How a virtual medical cannabis clinic is working on healthcare coverage for THC
Cannabis Clinician Summary
Virtual medical cannabis clinics are exploring insurance coverage for THC-based treatments as a potential way to reduce overall healthcare costs, which clinicians and insurers increasingly recognize.
New Report: Poland Medical Cannabis Market Data Shows Full Post-Ban Recovery
Poland’s medical cannabis market recovered after in-person consultation requirements temporarily reduced telemedicine access, providing clinicians insight into regulatory impacts on patient care delivery models.
DPH Commissioner goes ‘On the Record’ about measles outbreaks, cannabis – YouTube
Public health officials discuss rising THC potency in legal cannabis products and health risks for adolescents, relevant to clinical assessment and patient counseling on product strength.
The Coming Divide in Cannabis: Why the U.S. Market Remains Out of Reach for Global Operators
Summary for Cannabis Clinicians
The U.S. federal cannabis scheduling creates regulatory barriers affecting cannabinoid medicine development, limiting clinicians’ access to evidence-based treatments and pharmaceutical options.
Brazil’s Cannabis Crossroads: New Rules, Old Truths, and the Road Ahead
Brazil’s updated cannabis framework integrates medical cannabis into formal healthcare with domestic cultivation oversight and explicit THC product provisions, affecting clinical practice standardization and patient access.
Branford industrial site sold, to become cannabis growing operation – The Wilton Bulletin
Summary
An industrial site in Branford was sold and will be converted into a cannabis growing operation, relevant to clinicians who prescribe cannabis or monitor patient access to cultivation and supply sources.
Most cannabis users are ‘non-problematic’, Canadian data shows – leafie
Cannabis Article Summary
Canadian data demonstrates most cannabis users don’t develop problematic patterns, helping clinicians distinguish typical use from disorder and reduce stigma-driven barriers to appropriate patient care.
US Cannabis Rescheduling: A Victory or a Federal Trap?
Federal rescheduling from Schedule I to III changes cannabis’s legal classification but doesn’t automatically legitimize state programs, creating ongoing regulatory uncertainty that clinicians must navigate.
Rapid Dose Therapeutics Advances Cannabinoid Studies for QuickStrip Drug Delivery Platform
Summary for Cannabis Clinicians
Rapid Dose Therapeutics is developing oral thin film technology to deliver cannabinoids with improved dosing precision and faster onset compared to traditional methods.
Scientists Reveal What Types Of Food The Marijuana ‘Munchies’ Make You Crave The Most
Cannabis users experience altered food preferences toward high-calorie, high-fat and high-sugar foods, which clinicians should consider when counseling patients about appetite changes and nutritional health.
Key Congressional Committee Set To Vote On Delaying Federal Hemp THC Ban Next Week
Congressional committee voting on delaying federal hemp-derived THC product ban addresses regulatory gaps in product safety, labeling accuracy, and dosing standards affecting clinical practice.
Wisconsin Democrats File Bill to Legalize Adult-Use, Medical Cannabis; Regulate Intoxicating Hemp
Wisconsin Democrats proposed legislation establishing adult-use and medical cannabis legalization with state health department oversight, directly impacting clinical cannabis practice and patient access.
Rare Cannabinoid Company Expands Mood Collection with New THC-Free CBC Gummies …
Summary for Cannabis Clinician
This article covers CBC, a non-intoxicating cannabinoid with distinct endocannabinoid system mechanisms, relevant for clinicians seeking THC-free mood support options with potentially unique pharmacological properties.
Maryland Senate Delays Vote on Bill Allowing Firefighters to Use Medical Cannabis Off-Duty
Maryland legislation would allow off-duty firefighters and first responders to use medical cannabis for occupational-related conditions like chronic pain, PTSD, and sleep disorders.
Upper Township unanimous for weed zone, overriding complaints from residents
Summary
Upper Township unanimously approved a cannabis retail zone despite resident opposition, establishing local licensing framework relevant to clinicians’ patient referral options and legal supply access.
Medical cannabis delivery app seeing growth in the DMV and Jamaica | DC News Now
This article covers medical cannabis delivery services in the DMV region and Jamaica, relevant to clinicians managing patients with mobility or chronic illness limitations.
Cannabis industry launches organization to further US policy changes with members from …
Summary for Cannabis Clinician
Industry groups are organizing to influence US cannabis policy during federal rescheduling discussions, which affects prescribing regulations and patient access to clinical cannabis.
The Best CBD for Seniors in 2026: Safe, Lab-Tested, and Easy to Use | stupidDOPE
This article reviews CBD products marketed to seniors for managing pain, sleep, and anxiety—relevant for clinicians assessing cannabinoid safety and efficacy in aging populations with polypharmacy concerns.
Indiana lawmakers miss deadline, killing key cannabis bill | News | wthitv.com
Indiana failed to pass cannabis reform legislation, leaving the state behind neighboring states in medical cannabis policy expansion—a concern for clinicians treating patients who may seek care elsewhere.
Hemp products had illegal THC amounts, mold, pesticides, and carcinogens, investigation finds
One-Sentence Summary
Unregulated hemp products contain mislabeled THC, mold, pesticides, and carcinogens, creating patient safety and legal compliance risks for clinicians recommending cannabis products.
Many NC candidates support medical marijuana legalization | Raleigh News & Observer
North Carolina candidates increasingly support medical marijuana legalization despite prior legislative failures, signaling potential policy changes affecting patient access and clinical practice opportunities.
Does Weed Make You Harder or Easier to Manipulate? – Herb
Cannabis impairs prefrontal cortex function affecting judgment and decision-making; clinicians should assess cognitive impacts when counseling patients on use risks and informed consent.
Aelis Farma’s AEF0117 THC Interaction Trial Withdrawn: What Investors Should Know
One Sentence Summary
Aelis Farma discontinued a clinical trial of AEF0117, a selective CB1 receptor inhibitor intended to treat THC-related adverse effects and cannabis use disorder, affecting a potential treatment option for clinicians.
Pres. Trump’s Marijuana Executive Mandate Accelerates MMJ International Holdings … – Newswire
Summary for Cannabis Clinician
This article covers how Trump administration policy changes on cannabis scheduling may affect international pharmaceutical-grade cannabis manufacturers, creating regulatory clarification opportunities relevant to clinical cannabis practice.
Veterans Groups Urge Congress To Expand Psychedelics And Marijuana Access To …
Veterans organizations seek expanded VA access to cannabis and psychedelics to address high veteran suicide rates, reflecting clinical evidence supporting these treatments.
The Fire Station partners with Citizens for a Safe & Clean Lake Superior for cannabis vape …
Summary
The Fire Station retail location collaborates with a community environmental organization regarding cannabis vape products and Lake Superior water quality protection.
Boulder and CBD: The Entourage Effect Explained | About Boulder County Colorado
Summary for Cannabis Clinician
The entourage effect describes how multiple cannabis plant compounds work together to produce therapeutic effects that single isolated compounds cannot achieve alone.
Indiana S.B. 250 could close Lafayette hemp-beverage sales without a key amendment
Indiana S.B. 250 could prohibit hemp-derived cannabinoid beverages, affecting patient access to regulated products currently used for symptom management.
The Best CBD for Immune Support and Daily Resilience in 2026 | stupidDOPE | Est. 2008
Summary for Cannabis Clinician
This article examines CBD’s interaction with the endocannabinoid system for immune and homeostatic regulation, relevant to evidence-based clinical applications in inflammation and stress management.
Louisiana Lawmakers Advance Adult-Use Cannabis Pilot Bill – KQKI News
Louisiana lawmakers are advancing a limited adult-use cannabis pilot program, which is clinically relevant for understanding regulatory frameworks and real-world patient access patterns in traditionally restrictive states.
As Congress debates hemp-derived THC ban, Pa. lawmakers look for other options
Summary for Cannabis Clinician
Pennsylvania lawmakers are addressing regulatory gaps in hemp-derived THC products to establish state oversight of intoxicating cannabis compounds currently unregulated under existing frameworks.
West Virginia House approves bill allowing medical cannabis edibles | WV News
West Virginia’s House approved legislation to add edible formulations to its medical cannabis program, expanding treatment options for patients unable to use inhaled cannabis.
The Wait is Over: Medical Cannabis set to roll out in April | WHNT.com
Alabama’s medical cannabis program launch in April enables clinicians to recommend cannabis for qualifying patients with conditions including chronic pain, PTSD, and anxiety.
Branford industrial site sold, to become cannabis growing operation – New Haven Register
Summary
An industrial site in Branford was sold and will be converted into a cannabis cultivation facility, representing commercial expansion of the legal cannabis market.
Utah Lawmakers Pass Bill To Support Clinical Trials On Psychedelics For Veterans’ Mental Health
Summary
Utah lawmakers approved legislation enabling clinical trials of psychedelics for veteran mental health treatment, expanding therapeutic research beyond cannabis into complementary psychedelic compounds.
The Best CBD for Mental Clarity and Focus in 2026 | stupidDOPE | Est. 2008
This article discusses CBD’s pharmacological mechanisms affecting stress, mood, and cognition through multiple receptor systems—relevant for clinicians evaluating CBD for mental health applications.
Study uncovers another reason not to skimp on sleep – ASU News
Sleep deprivation impairs prefrontal cortex function, increasing impulsive decision-making and substance use risk—clinicians should assess sleep quality when evaluating cannabis use patterns and relapse risk.
OCM issues precautionary recall for select cannabis products tested by Keystone Lab – CBS 6 Albany
Cannabis Testing and Recall Summary
**Sentence:** OCM’s precautionary recall highlights how third-party lab testing failures can compromise product safety verification, requiring clinicians to verify current testing status before recommending cannabis to patients.
High Tide joins U.S. National Compassionate Care Council | HITI Stock News
High Tide’s involvement with the U.S. National Compassionate Care Council signals industry efforts to standardize medical cannabis access protocols, which matters to clinicians seeking consistent evidence-based treatment guidelines.
Oklahoma Seeks to Backtrack on Medical Marijuana as Pitfalls Multiply
Oklahoma’s rapidly expanding medical cannabis program faces regulatory challenges including oversaturation, product inconsistency, and diversion concerns, prompting potential rollbacks that could affect clinician prescribing practices.
SA risks missing R40bn hemp industry opportunity without coherent strategy – Business Day
South Africa faces potential loss of a R40 billion hemp industry opportunity due to lack of coherent national strategy, affecting agricultural development and CBD product supply chains.
Kearney man charged with selling THC cartridges to undercover officer near school – Nebraska TV
Summary
A Kearney, Nebraska resident was charged with selling THC cartridges to an undercover officer in a school zone, highlighting enforcement of laws restricting cannabis product sales near educational institutions.
The Office Is Issuing A Recall On Multiple Adult-Use Cannabis Products Tested By Keystone …
Cannabis Product Recall Summary
Multiple adult-use cannabis products tested by Keystone laboratory are being recalled due to safety or labeling concerns identified during regulated testing, requiring clinicians to advise patients on product safety.
Linnea Achieves CEP Certification for Cannabidiol Isolate – Morningstar
Summary for Cannabis Clinicians
CEP certification confirms cannabidiol isolate meets strict European pharmaceutical standards for identity, purity, and manufacturing consistency, ensuring reliable clinical quality.
Substance use on the rise among Gen Z in their early 20s – Medical Xpress
Summary
Gen Z’s increasing substance use in early adulthood affects clinical presentation, treatment planning, and patient outcomes for cannabis use disorder interventions in this demographic.
Senate Bill would repeal 24% wholesale tax on marijuana – WTVB
A proposed Senate bill seeks to repeal a 24% wholesale marijuana tax implemented January 2026, which cannabis clinicians should monitor as tax policy affects product pricing and patient access.
R40bn opportunity for hemp industrialisation in South Africa requires policy support – LSF study
South Africa’s hemp industrialization could generate R40 billion economically, requiring regulatory policy support to enable clinical cannabis practitioners to operate within a formal, sustainable industry framework.
Bill to require stricter packaging requirements for marijuana edibles dies in Oregon legislature
Oregon legislators failed to pass packaging requirements for cannabis edibles, including individual wrapping and standardized dosing per piece, potentially limiting product safety measures clinicians recommend to prevent accidental pediatric exposure.
Germany’s Medical Cannabis Boom: Data-Driven Insights for Investors | INN
Germany’s medical cannabis market growth is documented through patient data analysis, providing clinicians evidence-based insights into therapeutic effectiveness and treatment outcomes.
New study reveals how many Americans use CBD — and why | GreenState
Summary for Cannabis Clinician
This study documents CBD usage prevalence and demographic patterns across American populations, providing clinicians with epidemiological data on patient populations and common therapeutic intentions.
New Report: Poland Medical Cannabis Market Data Shows Full Post-Ban Recovery
Poland’s medical cannabis market recovery post-ban demonstrates regulatory progress in Europe and restored patient access to medical cannabis treatment options.
Wisconsin Democrats Introduce Cannabis Legalization Bill – Law360 Tax Authority
Wisconsin Democrats propose recreational cannabis legalization with regulatory and tax frameworks, affecting clinical practice standards, patient access, and healthcare provider obligations in the state.
CBD oil restores quality of life for sisters, sharing concerns about new regulations with hemp …
Summary for Cannabis Clinician
Two sisters report quality-of-life improvements using THCA-containing hemp CBD products while advocating against regulatory restrictions on precursor cannabinoids.
ACLU previews cannabis & guns arguments for Supreme Court (Newsletter: February 26, 2026)
Summary for Cannabis Clinicians
The ACLU is challenging whether federal cannabis prohibition can disqualify state-legal cannabis users from gun ownership, directly affecting clinical documentation and patient counseling practices.
Texas Voters Disapprove Of How State Officials Are Handling Marijuana And THC Laws, Poll Shows
Texas voters disapprove of state marijuana/THC law management, reflecting regulatory inconsistencies in hemp-derived THC products that clinicians must navigate for patient care.
Bridging the Gap: Medical Cannabis, Regulators, and the Reality of Clinical Accountability
Cannabis Clinician Summary
This article examines tensions between patient demand for medical cannabis and regulatory gaps that prevent standardized outcome tracking—critical for clinicians establishing treatment protocols.
March 5 webinar offers parents lessons on drug/alcohol trends – Rice County, MN
This webinar educates parents on current drug and alcohol trends affecting youth, including cannabis use and health impacts, relevant to clinicians treating adolescent cannabis patients.
Michigan’s Marijuana Tax Experiment Should Be An Urgent Warning To Other States (Op-Ed)
Michigan’s high cannabis taxes are driving consumers to illicit markets, threatening legal business viability—a key consideration for clinicians advising patients on regulated product access and market sustainability.
Curaleaf Earnings: International Growth Offsets Domestic Decline from Continued Price Compression
Cannabis Clinician Summary
Curaleaf’s earnings show legal cannabis market pressure from illicit competition and unregulated hemp products, affecting industry profitability and potentially access to regulated medicinal cannabis products.
Kentucky bill would expand cannabis drink sales beyond liquor stores – WKYT
Cannabis Clinician Summary
Kentucky’s SB 223 expands cannabis beverage sales channels beyond liquor stores, requiring clinicians to understand broader distribution pathways and potential patient access patterns for dosing counseling.
Advanced drug testing improves patient care at MUSC
Advanced drug testing at MUSC enables more accurate, cost-effective THC detection, helping clinicians better understand patient cannabis use patterns and customize treatment approaches.
As lawmakers in Richmond continue debating a path forward for retail marijuana sales …
Virginia lawmakers lack comprehensive scientific evidence on cannabis health impacts while developing retail marijuana regulations, creating evidence gaps relevant to clinical practice and patient care.
Europe’s Medical Cannabis Market Surges Toward $13 Billion: Last Week in Weed Feb. 23 …
Europe’s medical cannabis market expansion toward $13 billion reflects growing regulatory approval and commercial availability, directly expanding treatment options and clinical access for practitioners.
Facing Hemp Ban, PA Lawmakers Race to Regulate THC Drinks and Products
Cannabis Clinician Summary
Pennsylvania is establishing state regulations for THC-containing hemp products amid federal enforcement, creating clinical implications for patient access and product safety standards.
Ricketts addresses Congress leaving Nebraska off list protecting state medical cannabis laws
Senator Ricketts declined to clarify his position on federal protections for state medical cannabis laws, affecting regulatory certainty for Nebraska medical cannabis programs and clinicians.
The Wait is Over: Medical Cannabis set to roll out in April | WKRG.com
Alabama’s medical cannabis program launching in April 2024 provides clinicians with regulatory framework and dispensary access to recommend cannabis products to eligible patients.
From Billion-Dollar Hemp Drinks to FDA Cease-and-Desist Letters: The Cannabis Industry’s …
The FDA is escalating enforcement against cannabis beverage companies making health claims, creating regulatory risk that clinicians must monitor when advising patients on product safety and legitimacy.
Popular Diabetes Drugs May Help Combat Multiple Addictions, Major Study Shows
Cannabis Clinician Summary
This article reports on diabetes medications’ potential to treat multiple substance addictions, which is relevant for clinicians managing cannabis use disorder and co-occurring addiction conditions.
Digest-Level Clinical Commentary
Clinical Reflection
These items collectively signal that cannabis medicine is transitioning from a niche practice toward mainstream medical integration, as evidenced by emerging clinical evidence for specific cannabinoid applications (particularly CBD and CBG for metabolic disease) alongside the maturation of regulatory frameworks across multiple states and countries. However, this expansion is occurring unevenly and sometimes at odds with clinical safety priorities, as exemplified by the tension between potency regulations and industry pushback, which suggests practitioners will need to become increasingly fluent in both the pharmacology and the rapidly shifting policy landscape to provide evidence-based guidance. The proliferation of both rigorous clinical trials and poorly regulated commercial products means that patient education about product standardization and therapeutic specificity will become central to responsible cannabis medicine practice.
Clinical Perspective
These items reflect an emerging bifurcation in cannabis policy and research: while regulatory frameworks struggle to standardize THC potency and product availability across jurisdictions, preclinical and clinical evidence continues to accumulate for specific cannabinoid applications in metabolic and pain conditions. The disproportionate attention to CBD and CBG for hepatic and inflammatory endpoints, alongside growing anxiety disorder trial data, suggests clinical interest is progressively shifting toward non-intoxicating compounds with measurable therapeutic profiles rather than whole-plant formulations. Simultaneously, the persistent regulatory fragmentation—particularly regarding beverage restrictions and potency caps—indicates that public health governance has not yet aligned with the emerging evidence base on differential cannabinoid safety and efficacy profiles.
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
